8-K current report · filed Nov 2, 2026

Emergent BioSolutions Inc. (EBS) 8-K Current Report: November 2, 2026

Item 2.02Item 7.01Item EX-99.2Item EX-99.1EBS overview

Short answer

Emergent BioSolutions Inc. (EBS) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1). Emergent BioSolutions announced financial and operating results for the quarter ended September 30, 2026.

Emergent BioSolutions Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Emergent BioSolutions announced financial and operating results for the quarter ended September 30, 2026
  • Detailed results and management commentary appear in furnished Exhibit 99.1, the company’s earnings press release

Item 7.01 · Regulation FD Disclosure

  • Earnings call scheduled November 2, 2026, covering results for quarter ended September 30, 2026
  • Earnings Call Slides furnished as Exhibit 99.2, providing investor presentation materials for the quarterly results discussion

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $110.0M, down 52% year over year, with Smallpox MCM down 68% and Other Products down 87%
  • Net loss $32.7M, adjusted net loss $18.7M, and adjusted EBITDA loss $4.6M, signaling sharply weaker profitability
  • Gross margin fell to 14% from 54%, while adjusted gross margin declined to 28% from 62% on unfavorable mix and lower volumes
  • Full-year revenue forecast cut to $600-$645M, adjusted EBITDA to $110-$140M, and adjusted net income to $(10)-$20M
  • $75M of senior unsecured notes repurchased, supporting deleveraging, while CFO Rich Lindahl retires December 31, 2026

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 revenue $110M, within prior guidance, but YTD revenue fell to $500M from $594M
  • FY 2026 guidance reduced to revenue $600M-$645M and Adjusted EBITDA $110M-$140M
  • YTD Adjusted EBITDA $128M, 25% margin, with $122M operating cash flow
  • Liquidity $226M, including $176M cash, while net leverage increased to 2.4x from 1.9x
  • Debt reduction continued with $75M unsecured bond principal repurchased and $68M cash deployed

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Emergent BioSolutions Inc. 8-K filings

Get the next EBS 8-K as it lands

Follow EBS for push alerts, or ask the research agent what this filing means.